Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like Angina

This study is currently recruiting participants.
Verified August 2013 by Centre Hospitalier Universitaire de Saint Etienne
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT01290770
First received: February 3, 2011
Last updated: August 6, 2013
Last verified: August 2013

February 3, 2011
August 6, 2013
February 2011
February 2014   (final data collection date for primary outcome measure)
correlation between Lp(a) and TFPI activity [ Time Frame: day 1 ] [ Designated as safety issue: No ]
Establish correlation between Lp(a) rate and TFPI activity in obese patients with chest pain like stable angina
Same as current
Complete list of historical versions of study NCT01290770 on ClinicalTrials.gov Archive Site
  • Correlation between Lp(a) and TFPI resistance [ Time Frame: day 1 ] [ Designated as safety issue: No ]
    Establish correlation between Lp(a) rate and TFPI resistance at inclusion and 1 month after aspirin treatment
  • Correlation between lp(a) rate and TFPI activity [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    Establish the correlation, 1 month after initiation of aspirin treatment, between lp(a) rate and TFPI activity
  • thrombin generation [ Time Frame: day 1 ] [ Designated as safety issue: No ]
    describe thrombin generation with calibrated automated thrombinography technique in obese patient with chest pain like angina and hight Lp(a)rate
  • Correlation between Lp(a) and TFPI resistance [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    Establish correlation between Lp(a) rate and TFPI resistance at inclusion and 1 month after aspirin treatment
Same as current
Not Provided
Not Provided
 
Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like Angina
Search a Correlation Between Lipoprotein(a) Rate and TFPI(Tissue Factor Pathway Inhibitor)Activity in Obese Patients With Chest Pain Like Angina

Atherosclerotic cardiovascular disease is a leading cause of mortality in our countries. Clinically, symptoms could be chest pain suggesting stable angina. Atherosclerosis is influenced by cardiovascular risk factors which obesity (Body Mass Index>30). Obesity is associated with an increase risk of cardiovascular complications.

Lipoprotein(a) is regarded as an independent risk factor for premature cardiovascular disease. Lp(a) is composed of low-density lipoprotein - like particle bound to glycoprotein molecule: apolipoprotein(a). Plasma levels are determinated to more than 90% by genetic factors (no significant influence of statin, weight, lifestyle factor: diet, exercise). Two study with few patients have found that aspirin lowers serum Lp(a) levels. Elevated Lp(a) is a risk factor for recurrent coronary events in obese patient.

Atherosclerosis is associated with imbalance of coagulation. TFPI (tissue factor pathway inhibitor) is the earliest inhibitor of the blood coagulation process, natural direct inhibitor of tissue factor. In-vitro, TFPI activity is inhibited by high Lp(a) .

The aim of this study is to research reverse association between Lp(a) and TFPI activity in obese patient with chest pain like stable angina suggesting atherosclerotic heart disease and effect of aspirin.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

whole blood and serum

Non-Probability Sample

obese men with chest pain like stable angina

Atherosclerosis
Other: blood sample
blood sample at inclusion and 1 month after inclusion
obese men
obese men with chest pain like angina
Intervention: Other: blood sample
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
April 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Major
  • Men
  • Obese BMI>30
  • No aspirin treatment before inclusion
  • Coronary exploration: coronary angiography or tomography coronary angiography
  • Chest pain like stable angina

Exclusion Criteria:

  • Women
  • Severe hepatic insufficiency
  • Inflammatory disease
  • Neoplasia
  • Protein S deficiency
  • Aspirin treatment 10 days before inclusion
  • Oral anticoagulant treatment at inclusion
  • Heparin or low molecular weight heparin treatment at inclusion
Male
18 Years and older
No
Contact: Arnauld Garcin +33(4)77120286 agarcin34@yahoo.fr
France
 
NCT01290770
1008178
No
Centre Hospitalier Universitaire de Saint Etienne
Centre Hospitalier Universitaire de Saint Etienne
Not Provided
Principal Investigator: Brigitte TARDY, MD CHU de Saint-Etienne
Centre Hospitalier Universitaire de Saint Etienne
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP